Bradykinin modulates mucin secretion but not synthesis from an intestinal goblet cell line.
The effect of the inflammatory mediator bradykinin on glycoprotein synthesis and mucin secretion in the human colonic adenocarcinoma cell line HT29-18N2 was examined. Bradykinin, at a threshold of 0.01 microM, accelerated the rate of mucin discharge as assessed by a mucin-specific ELISA. Using immunofluorescence microscopy, a thick meshwork of extracellular mucus was observed over bradykinin-treated monolayers but not mock-treated controls. Morphometric analysis of bradykinin-treated monolayers revealed no decreases in intracellular mucin stores or any other easily discernable morphological alteration. The ability of the cyclooxygenase inhibitors indomethacin and naproxen to decrease the response to bradykinin by approximately 68% indicates the effect is mediated, at least partially, through the generation of prostaglandins. Bradykinin did not alter the rate of incorporation of 3H-glucosamine into newly synthesized glycoproteins. Bradykinin-accelerated mucin secretion may be linked to the depletion of intracellular mucin stores in the inflammatory bowel disease ulcerative colitis.
Stanley
C M
CM
Division of Biological Sciences, University of Missouri, Columbia 65211.
Phillips
T E
TE
D000230:Adenocarcinoma / Q000378:metabolism*; D001920:Bradykinin / Q000502:physiology*; D003110:Colonic Neoplasms / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D005944:Glucosamine / Q000378:metabolism; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D009077:Mucins / Q000096:biosynthesis / Q000378:metabolism*; D009288:Naproxen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D009077:Mucins; D009288:Naproxen; D005944:Glucosamine; D001920:Bradykinin; D007213:Indomethacin